Past, present, and future of annexin A5: From protein discovery to clinical applications

Journal of Nuclear Medicine

Volumn 46, Issue 12, 2005, Pages 2035-2050

  Boersma, Hendrikus H ^a   Kietselaer, Bas L J H ^b   Stolk, Leo M L ^a   Bennaghmouch, Abdelkader ^b   Hofstra, Leonard ^b   Narula, Jagat ^c   Heidendal, Guido A K ^a   Reutelingsperger, Chris P M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Annexin A5; Cancer; Cardiovascular disease; Clinical applications; Diagnostic tool; Radiopharmaceutical

Indexed keywords

4,5 BIS(THIOACETAMIDO)PENTANOYL ANNEXIN A5 TC 99 M; ANNEXIN A5 F 18; ANNEXIN A5 I 123; ANNEXIN A5 I 124; ANNEXIN A5 I 125; ANNEXIN A5 IN 111; ANNEXIN A5 TC 99 M; HYDRAZINONICOTINAMIDE ANNEXIN A5 TC 99 M; LIPOCORTIN 5; N 1 IMNINO 4 MERCAPTOBUTYL ANNEXIN A5 TC 99 M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANNEXIN; CALCIUM; DIAGNOSTIC AGENT; HALOGEN; INDIUM; MACROGOL DERIVATIVE; PHOSPHATIDYLSERINE; RADIOISOTOPE; TECHNETIUM; THALLIUM;

ATHEROSCLEROSIS; BIOCHEMISTRY; CANCER; CELL DEATH; HEART INFARCTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; ADULT; ANIMAL; APOPTOSIS; CARDIOVASCULAR DISEASE; CHEMISTRY; HEART MUSCLE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUSE; NEOPLASM; PATHOLOGY; PERFUSION; PROTEIN TERTIARY STRUCTURE; SARCOMA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY IMAGING; X RAY;

ADULT; ANIMALS; ANNEXIN A5; ANNEXINS; APOPTOSIS; ATHEROSCLEROSIS; CALCIUM; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASES; HALOGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MYOCARDIUM; NEOPLASMS; PERFUSION; PHOSPHATIDYLSERINES; POLYETHYLENE GLYCOLS; PROTEIN STRUCTURE, TERTIARY; RADIOISOTOPES; RADIOPHARMACEUTICALS; SARCOMA; TECHNETIUM; THALLIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING; X-RAYS;

EID: 33644876123     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Chen M, He H, Zhan S, et al. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem. 2001;276: 30724-30728.
2. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356:209-212.
3. Kolodgie FD, Narula J, Guillo P, Virmani R. Apoptosis in human atherosclerotic plaques. Apoptosis. 1999;4:5-10.
4. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2:589-598.
5. Dumont EA, Reutelingsperger CP, Smits JF, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med. 2001;7:1352-1355.
6. Dumont EA, Hofstra L, van Heerde WL, et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation. 2000;102:1564-1568.
7. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A. 1998;95:6349-6354.
8. Koopman G, Reutelingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420.
9. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82: 331-371.
10. Bohn H, Kraus W. Isolation and characterization of a new placenta specific protein (PP10) [in German]. Arch Gynecol. 1979;227:125-134.
11. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem. 1985;151:625-629.
12. Reutelingsperger CP, Kop JM, Hornstra G, Hemker HC. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation: inhibition of the phospholipid-dependent factor-Xa-catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phospholipids. Eur J Biochem. 1988;173:171-178.
13. Reutelingsperger CP. Annexins: key regulators of haemostasis, thrombosis, and apoptosis. Thromb Haemostasis. 2001;86:413-419.
14. Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun. 2004;322:1166-1170.
15. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. Traffic. 2004;5:571-576.
16. Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5:219.
17. Maurer-Fogy I, Reutelingsperger CP, Pieters J, et al. Cloning and expression of cDNA for human vascular anticoagulant, a Ca2+-dependent phospholipid-binding protein. Eur J Biochem. 1988;174:585-592.
18. Kaplan R, Jaye M, Burgess WH, Schlaepfer DD, Haigler HT. Cloning and expression of cDNA for human endonexin II, a Ca2+ and phospholipid binding protein. J Biol Chem. 1988;263:8037-8043.
19. Iwasaki A, Suda M, Nakao H, et al. Structure and expression of cDNA for an inhibitor of blood coagulation isolated from human placenta: a new lipocortin-like protein. J Biochem (Tokyo). 1987;102:1261-1273.
20. Blankenberg FG, Strauss HW. Will imaging of apoptosis play a role in clinical care? A tale of mice and men. Apoptosis. 2001;6:117-123.
21. Fadok V, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207-2216.
22. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121-1132.
23. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Ab1. J Exp Med. 1995;182:1545-1556.
24. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods. 1995;184:39-51.
25. Homburg CH, de Haas M, von dem Borne AE, et al. Human neutrophils lose their surface Fc gamma RIII and acquire annexin V binding sites during apoptosis in vitro. Blood. 1995;85:532-540.
26. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med. 2005;11:725-730.
27. Fadok VA, Henson PM. Apoptosis: giving phosphatidylserine recognition an assist-with a twist. Curr Biol. 2003;13:R655-R657.
28. McLaughlin R, Kelly CJ, Kay E, Bouchier-Hayes D. The role of apoptotic cell death in cardiovascular disease. Ir J Med Sci. 2001;170:132-140.
29. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005;57:187-215.
30. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626-629.
31. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther. 2001;92:57-70.
32. Zimmermann KC, Green DR. How cells die: apoptosis pathways. J Allergy Clin Immunol. 2001;108(suppl):S99-S103.
33. van Engeland M, Kuijpers HJ, Ramaekers FC, Reutelingsperger CP, Schutte B. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res. 1997;235:421-430.
34. Kenis H, van Genderen H, Bennaghmouch A, et al. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem. 2004;279:52623-52629.
35. Vriens PW, Blankenberg FG, Stoot JH, et al. The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg. 1998;116:844-853.
36. Post AM, Katsikis PD, Tait JF, et al. Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med. 2002;43:1359-1365.
37. Glaser M, Collingridge DR, Aboagye EO, et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot. 2003;58:55-62.
38. 18F-Labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging. 2004;31:469-474.
39. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7:1347-1352.
40. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004;350:1472-1473.
41. Hofstra L, Dumont EA, Thimister PW, et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA. 2001;285:1841-1842.
42. van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol. 2003;21:3483-3487.
43. 99mTc-annexin AS. Br J Radiol. 2003;76:553-560.
44. Verbruggen A. Bifunctional chelators for technetium-99m. In: Mather SJ, ed. Current Directions in Radiopharmaceutical Research and Development. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996:31-46.
45. Lahorte CM, Vanderheyden JL, Steinmetz N, et al. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging. 2004;31:887-919.
46. 99mTc by derivatization with 1-imino-4-mercaptobutyl groups. In: Nicolini M, Bandolini G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3. Verona, Italy: Cortina International; 1990:595-604.
47. 99mTc-annexin V. J Nucl Med. 2001;42:382-387.
48. 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med. 2001;28:1373-1378.
49. Stratton JR, Dewhurst TA, Kasina S, et al. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation. 1995;92:3113-3121.
50. Kasina S, Rao TN, Srinivasan A, et al. Development and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J Nucl Med. 1991;32:1445-1451.
51. 99mTc-EC-annexin V. Cancer Biother Radiopharm. 2001;16:73-83.
52. Boersma HH, Stolk LM, Kenis H, et al. The ApoCorrect assay: a novel, rapid method to determine the biological functionality of radiolabeled and fluorescent annexin A5. Anal Biochem. 2004;327:126-134.
53. 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med. 2003;44:947-952.
54. Tait JF, Brown DS, Gibson DF, Blankenberg FG, Strauss HW. Development and characterization of annexin V mutants with endogenous chelation sites for (99m)Tc. Bioconjug Chem. 2000;11:918-925.
55. Tait JF, Smith C, Gibson DF. Development of annexin V mutants suitable for labeling with Tc(i)-carbonyl complex. Bioconjug Chem. 2002;13:1119-1123.
56. 99mTc-annexin V. J Nucl Med. 2005;46:807-815.
57. Tait JF, Cerqueira MD, Dewhurst TA, et al. Evaluation of annexin V as a platelet-directed thrombus targeting agent. Thromb Res. 1994;75:491-501.
58. Russell J, O'Donoghue JA, Finn R, et al. Iodination of annexin V for imaging apoptosis. J Nucl Med. 2002;43:671-677.
59. 123I-rh-annexin V in mice and humans. Nucl Med Commun. 2003;24: 871-880.
60. 123I-labelled human recombinant annexin V. Biomol Eng. 2001;17:51-53.
61. 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl Radiat Isot. 2003;58:201-207.
62. Wen X, Wu QP, Ke S, et al. Improved radiolabeling of PEGylated protein: PEGylated annexin V for noninvasive imaging of tumor apoptosis. Cancer Biother Radiopharm. 2003;18:819-827.
63. 99mTc-labeled annexin V. J Nucl Med. 2004;45:1536-1541.
64. Thimister PW, Hofstra L, Liem IH, et al. In vivo detection of cell death in the area at risk in acute myocardial infarction. J Nucl Med. 2003;44:391-396.
65. 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J Nucl Med. 2004;45:309-312.
66. 111In-labeled annexin V. J Nucl Med. 2004;45:108-115.
67. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 2003;63: 1936-1942.
68. Blankenberg FG, Robbins RC, Stoot JH, et al. Radionuclide imaging of acute lung transplant rejection with annexin V. Chest. 2000;117:834-840.
69. Ogura Y, Krams SM, Martinez OM, et al. Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology. 2000;214:795-800.
70. 99mTc annexin V imaging of neonatal hypoxic brain injury. Stroke. 2000;31:2692-2700.
71. 99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis. Eur J Nucl Med Mol Imaging. 2003;30:232-238.
72. Narula J, Zaret BL. Noninvasive detection of cell death: from tracking epitaphs to counting coffins. J Nucl Cardiol. 2002;9:554-560.
73. Kown MH, Strauss HW, Blankenberg FG, et al. In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V. Am J Transplant. 2001;1:270-277.
74. 99mtechnetium-labelled annexin A5 [abstract]. Circulation. 2004;110:436.
75. Zhang J, McDonald KM. Bioenergetic consequences of left ventricular remodeling. Circulation. 1995;92:1011-1019.
76. Gomez AM, Valdivia HH, Cheng H, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 1997;276:800-806.
77. Haider N, Narula N, Narula J. Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling. J Card Fail. 2002;8(suppl):S512-S517.
78. Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000;157:1259-1268.
79. Kietselaer B, Thimister PWL, Reutelingsperger CPM, et al. Molecular imaging of cell death in intra-cardiac tumors: a new approach to differential diagnosis in cardiac tumors. Netherlands Heart J. 2002;10:312-316.
80. Reynen K. Frequency of primary tumors of the heart [editorial]. Am J Cardiol. 1996;77:107.
81. Blondeau P. Primary cardiac tumors: French studies of 533 cases. Thorac Cardiovasc Surg. 1990;38(suppl 2):192-195.
82. McAllister HA. Tumors of the cardiovascular system. In: Hartman WH, ed. Atlas of Tumor Pathology. Second series ed. Washington, DC: Armed Forces Institute of Pathology; 1978:20-25.
83. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62:6132-6140.
84. 99mTc-annexin V. J Nucl Med. 2003;44:92-97.
85. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766-2774.
86. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782-787.
87. 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol. 2004;72:333-339.